Anlon Healthcare Ltd

Anlon Healthcare Earnings Call Transcript: Key Takeaways

Q2 consolidated revenue ₹105.61 Cr (+102%), PAT ₹17.18 Cr (+84%). EBITDA margin recovered to 23.9%, still below the 25-30% guided band. FY27 revenue reiterated at ₹380-400 Cr.

Anlon Healthcare Investor Presentation: Key Takeaways

Q2FY27 consolidated revenue ₹105.6 Cr (+102.3% YoY), EBITDA ₹25.2 Cr (+84.1%), PAT ₹17.2 Cr (+84.4%). H1 FY27 revenue ₹193.2 Cr (+125.9%). Strategy: integrated API-to-formulations platform.

Anlon Healthcare Q2 FY27 Results: Net Profit ₹17.2 Cr, Up 84.9% YoY

Anlon Healthcare Ltd reported revenue from operations of ₹105.6 Cr (+102.3% YoY) and net profit of ₹17.2 Cr (+84.9% YoY) for Q2 FY27.

Key figure

Net profit ₹17.2 Cr · +84.9% YoY

Anlon Healthcare Preferential Issue

Anlon Healthcare received NSE and BSE in-principle approval for 8,05,35,651 preferential shares under a share swap. No cash consideration is stated.

Anlon Healthcare Board Meeting Date

Anlon Healthcare will hold a board meeting on 29 October 2026 to consider unaudited standalone and consolidated half-yearly results. The trading window is closed from 1 October to 31 October 2026.

Anlon Healthcare Other Announcement

Anlon Healthcare Limited filed the mandatory Regulation 74(5) certificate from its Registrar and Share Transfer Agent for the quarter ended September 30, 2026.

Anlon Healthcare Fund Raise of ₹250 Cr

Anlon Healthcare approved a preferential issue of convertible warrants for up to Rs. 250 Crore to raise funds for the company.

Value

₹250.0 Cr